| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/30/2004 | US20040191190 Cosmetic and/or pharmaceutical preparations containing plant extracts |
| 09/30/2004 | US20040191185 Ephedrine or fenfluramine; aluminum foil coated with a thin layer of drug is heated to form vapor; which condenses to form aerosol; rapid peak plasma concentration |
| 09/30/2004 | US20040191184 Delivery of muscle relaxants through an inhalation route |
| 09/30/2004 | US20040191183 Delivery of antiemetics through an inhalation route |
| 09/30/2004 | US20040191182 Delivery of analgesics through an inhalation route |
| 09/30/2004 | US20040191181 Vaporization of diphenhydramine from solid for breathing administerig |
| 09/30/2004 | US20040191180 Breathing analgesics after vaporization for administering pain killer for headaches |
| 09/30/2004 | US20040191179 Breathing antidepressants from aerosols for administering bupropion by heating on a solid support |
| 09/30/2004 | DE10202468A1 Pteridinderivate, Verfahren zu deren Herstellung und ihre Verwendung Pteridine derivatives, processes for their preparation and their use |
| 09/30/2004 | CA2519414A1 Methods of treating inflammatory diseases associated with bone destruction |
| 09/30/2004 | CA2519412A1 Combined use of g-csf and factors having angiogenic action |
| 09/30/2004 | CA2519084A1 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells |
| 09/30/2004 | CA2518227A1 Water-soluble phenylpyridazine derivative and medicine containing the same |
| 09/29/2004 | EP1462526A1 Novel tetronic acid derivative |
| 09/29/2004 | EP1462457A1 Cytotoxic protein and utilization thereof |
| 09/29/2004 | EP1462451A1 Novel crystalline forms of meloxicam and the preparation and interconversion methods thereof |
| 09/29/2004 | EP1462450A1 Substituted morpholine derivatives and their use as therapeutic agents |
| 09/29/2004 | EP1462449A1 Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels |
| 09/29/2004 | EP1462442A1 Crystals of bicalutamide and process for their production |
| 09/29/2004 | EP1462113A1 CELL GROWTH INHIBITOR CONTAINING ANTI-PepT ANTIBODY |
| 09/29/2004 | EP1462108A1 Interferon g (g) production promoter |
| 09/29/2004 | EP1461614A2 Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs3 upregulation |
| 09/29/2004 | EP1461449A2 System for monitoring bacterial tumor treatment |
| 09/29/2004 | EP1461445A2 Glycoprotein remodeling using endoglycanases |
| 09/29/2004 | EP1461436A1 Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| 09/29/2004 | EP1461427A2 Methods for targeted expression of therapeutic nucleic acid |
| 09/29/2004 | EP1461361A1 Negatively charged polysaccharide derivable from aloe vera |
| 09/29/2004 | EP1461358A1 Ifnar2 muteins, their production and use |
| 09/29/2004 | EP1461356A2 Hexa-, hepta-, and octapeptides having antiangiogenic activity |
| 09/29/2004 | EP1461347A1 2-o-(-d-glucopyranosyl)ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it |
| 09/29/2004 | EP1461340A2 Trioxane derivatives as antimalaria or anticancer compounds |
| 09/29/2004 | EP1461339A2 Spiroazacyclic compounds as monoamine receptor modulators |
| 09/29/2004 | EP1461336A2 1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists |
| 09/29/2004 | EP1461334A2 Pyrazole derived kinase inhibitors |
| 09/29/2004 | EP1461333A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 09/29/2004 | EP1461326A1 Benzothiazole- and benzoxazole-4,7-dione derivatives and their use as cdc25 phosphatase inhibitors |
| 09/29/2004 | EP1461325A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 09/29/2004 | EP1461321A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists |
| 09/29/2004 | EP1461319A1 Quinoline derivatives, synthesis method, and medicines containing said derivatives |
| 09/29/2004 | EP1461318A2 Tetrahydroquinoline analogues as muscarinic agonists |
| 09/29/2004 | EP1461313A1 Human adam-10 inhibitors |
| 09/29/2004 | EP1461311A2 Urea derivatives as vr1-antagonists |
| 09/29/2004 | EP1461306A1 Quaternary ammonium compounds and their use as antimuscarinic agents |
| 09/29/2004 | EP1461165A1 Metallic structures incorporating bioactive materials and methods for creating the same |
| 09/29/2004 | EP1461122A2 Treatment of genitourinary tract disorders |
| 09/29/2004 | EP1461084A2 Guanidinium transport reagents and conjugates |
| 09/29/2004 | EP1461083A1 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors |
| 09/29/2004 | EP1461081A2 Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection |
| 09/29/2004 | EP1461070A2 Combined use of a glp-1 compound and a modulator of diabetic late complications |
| 09/29/2004 | EP1461069A2 Combined use of a glp-1 compound and another drug for treating dyslipidemia |
| 09/29/2004 | EP1461068A1 Methods of compositions for normalizing lipid levels in mammalian tissues |
| 09/29/2004 | EP1461067A1 Compositions and method for treating hepatitis virus infection |
| 09/29/2004 | EP1461062A2 Composition and method for treating chronic allograft rejection |
| 09/29/2004 | EP1461059A1 Active substances for use in cosmetic and/or pharmaceutical products, obtainable from the fermentation of plant components and/or plant extracts |
| 09/29/2004 | EP1461039A1 Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| 09/29/2004 | EP1461038A1 Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders |
| 09/29/2004 | EP1461034A1 Substituted imidazolidines, method for the production thereof, use thereof as a drug or for diagnosis, and drug containing substituted imidazolidines |
| 09/29/2004 | EP1461015A2 Compositions containing both sedative and non-sedative antihistamines |
| 09/29/2004 | EP1461001A2 Cancer-associated epitope |
| 09/29/2004 | EP1460969A2 Prevention and treatment of androgen-deprivation induced osteoporosis |
| 09/29/2004 | EP1460964A2 Oral immunostimulation of mammals, birds, fish and reptiles from (1-4) linked b -d-mannuronic acid |
| 09/29/2004 | EP1419171A4 Methods for purification of an activated peg solution and for the synthesis of a modified hemoglobin solution |
| 09/29/2004 | EP1385874A4 Alpha conotoxin peptides with analgesic properties |
| 09/29/2004 | EP1351941B1 Bisaryl derivatives having fsh receptor modulatory activity |
| 09/29/2004 | EP1339502B1 Device for Coating an Object with an Active Ingredient and Method for Producing a Partial or Complete Active Ingredient Coating on and in Implants and Onplants as well as Use of or Product Obtained through such a Method |
| 09/29/2004 | EP1303527B1 Matrix metalloproteinase inhibitors |
| 09/29/2004 | EP1299350B1 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness |
| 09/29/2004 | EP1292288B1 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury |
| 09/29/2004 | EP1272180B1 Concentrated solutions of carvedilol |
| 09/29/2004 | EP1239882B1 Formulations of adenosine a1 agonists and 5ht3 agonists |
| 09/29/2004 | EP1210320B1 Aminobenzophenones as inhibitors of il-1beta and tnf-alpha |
| 09/29/2004 | EP1202959B1 Aminobenzophenones as inhibitors of il-1-beta and tnf-alpha |
| 09/29/2004 | EP1189905B1 Substituted heterocycle fused gamma-carbolines |
| 09/29/2004 | EP1181278B1 Cyclic amine derivatives and their uses |
| 09/29/2004 | EP1176960B1 Synergistic combination comprising roflumilast and a pde-3 inhibitor |
| 09/29/2004 | EP1169339B1 Macrocyclic peptides inhibiting the hepatitis c virus ns3 protease |
| 09/29/2004 | EP1169302B1 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists |
| 09/29/2004 | EP1165557B1 ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS |
| 09/29/2004 | EP1124563B1 Methods and compositions for the prevention of tolerance to bronchodilators |
| 09/29/2004 | EP1090116B1 Transgenic non-human animal which comprises an inactive peg3 gene, and the use thereof |
| 09/29/2004 | EP1084147B1 Process for producing immunoglobulins for intravenous administration and other immunoglobulin products |
| 09/29/2004 | EP1067965B1 Pharmaceutical composition for treating cerebral apoplexy and craniocerebral trauma |
| 09/29/2004 | EP1062201B1 Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors |
| 09/29/2004 | EP1012140B1 New amidino derivatives and their use as thrombin inhibitors |
| 09/29/2004 | EP1003526B1 Covalently linked n,o-carboxymethylchitosan and uses thereof |
| 09/29/2004 | EP1003503B1 Therapeutic combinations comprising amlodipin and atorvastatin |
| 09/29/2004 | EP1000059B1 Tricyclic vasopressin agonists |
| 09/29/2004 | EP0993439B1 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
| 09/29/2004 | EP0983300B1 Bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy |
| 09/29/2004 | EP0983080B1 Synthetic, statistic thymus peptide combination and its use as a preparation with immunological and/or endocrinological effect |
| 09/29/2004 | EP0969813B1 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker |
| 09/29/2004 | EP0914417B1 Human dnase ii |
| 09/29/2004 | EP0912533B1 Alkylaminobenzothiazole and -benzoxazole derivatives |
| 09/29/2004 | EP0912196B1 Use of a thexaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization |
| 09/29/2004 | EP0901487B9 2,3,6 trisubstituted-4(3h)-quinazolinones |
| 09/29/2004 | EP0736016B1 Trisubstituted phenyl derivatives, processes for their preparation and their use as phosphodiesterase (type iv) inhibitor |
| 09/29/2004 | CN1533392A Pyrazolopgrimidinone derivatives having PED 7 inhibitory activity |
| 09/29/2004 | CN1533391A Tricyclic compounds and their uses |
| 09/29/2004 | CN1533390A Drugs containing triazaspiro [5,5] undecane derivatives as the active ingredient |
| 09/29/2004 | CN1533388A Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |